全部文献期刊会议图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Tania D Pereira Chilima , Fabien Moncaubeig , Suzanne S. Farid
来源:[J].Biochemical Engineering Journal(IF 2.579), 2020, Vol.155
摘要:Abstract(#br)Estimations of the facility footprint and fixed capital investment (FCI) of cell therapy (CT) facilities need to consider the unique features of the single-use technologies (SUTs) selected for CT manufacture (e.g. cleanroom containment requirement, capacity, auto...
作者:Ruoyu Chen , Ling Li , Lu Feng ...
来源:[J].Biomaterials(IF 7.604), 2020, Vol.230
摘要:Abstract(#br)Cell therapy, the treatment of diseases using living cells, offers a promising clinical approach to treating refractory diseases. The global market for cell therapy is growing rapidly, and there is an increasing demand for automated methods that can produce large qua...
作者:Victoria Gutgarts , Tania Jain , Junting Zheng ...
来源:[J].Biology of Blood and Marrow Transplantation(IF 3.94), 2020
摘要:ABSTRACT(#br)Chimeric antigen receptor (CAR) T cell therapy using engineered cytotoxic T cells has shown promising responses in various hematologic malignancies. Cytokine release syndrome (CRS) and immune effector cell-associated neurologic syndrome (ICANS) are recognized toxic...
作者:Hideo Shichinohe , Masahito Kawabori , Hiroaki Iijima ...
来源:[J].BMC Neurology(IF 2.564), 2017, Vol.17 (1)Springer
摘要:... However, a recent breakthrough in cell therapy is expected to reverse the neurological sequelae of stroke. Although some pioneer studies on the use of cell therapy for treating stroke have been reported, certain problems remain unsolved. Recent studies have demonstrated that ...
作者:Hualong Yan , Yun-Bo Shi , Jing Huang
来源:[J].Cell & Bioscience(IF 3), 2017, Vol.7 (1)Springer
摘要:Induced pluripotent stem cells (iPSCs) hold great promises in cell therapy. However, the potential safety issues have dampened the enthusiasm of their clinical development. One of the biggest concerns came from the observations that genomic alterations exist in iPSCs. Using next...
作者:Wenjing Wu , Yajun Yin , Jie Zhong ...
来源:[J].Lipids in Health and Disease(IF 2.015), 2017, Vol.16 (1)Springer
摘要:... The purpose of this study was to test the possibility of using cell therapy to alleviate LPL deficiency.
作者:Zhenguang Wang , Zhiqiang Wu , Yang Liu ...
来源:[J].Journal of Hematology & Oncology(IF 4.458), 2017, Vol.10 (1)Springer
摘要:Chimeric antigen receptor (CAR)-engineered T cells (CAR-T cells) have yielded unprecedented efficacy in B cell malignancies, most remarkably in anti-CD19 CAR-T cells for B cell acute lymphoblastic leukemia (B-ALL) with up to a 90% complete remission rate. However, tumor antigen e...
作者:Francesco Agostini , Jerry Polesel , Monica Battiston ...
来源:[J].Journal of Translational Medicine(IF 3.459), 2017, Vol.15 (1)Springer
摘要:Standardized animal-free components are required for manufacturing cell-based medicinal products. Human platelet concentrates are sources of growth factors for cell expansion but such products are characterized by undesired variability. Pooling together single-donor products impr...
作者:Mingxue Fan , Minghao Li , Lipeng Gao ...
来源:[J].Journal of Hematology & Oncology(IF 4.458), 2017, Vol.10 (1)Springer
摘要:... With the clinical success of anti-CD19 chimeric antigen receptor (CAR) T cell therapies against B-lineage malignancies, many studies have attempted to translate the success of CAR T cell therapy to other malignancies, including AML. This review summarizes the current advances...
作者:Erhao Zhang , Hanmei Xu
来源:[J].Journal of Hematology & Oncology(IF 4.458), 2017, Vol.10 (1)Springer
摘要:Adoptive cell therapy using chimeric antigen receptor (CAR)-engineered T cells has emerged as a very promising approach to combating cancer. Despite its ability to eliminate tumors shown in some clinical trials, CAR-T cell therapy involves some significant safety challenges,...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×